Arthur A. Levin PhD
VP & CDO and President, US Operations
Dr. Arthur Levin has over 15 years of experience in RNA-based research and development and 25 years of experience in the pharmaceutical industry. Before joining Santaris Pharma, Dr. Levin consulted for leading biotechnology and pharmaceutical companies, conducting research and development in RNA-based therapies such as mRNA, microRNA, and siRNA. Prior to consulting, Dr. Levin was Senior Vice President of Development at Isis Pharmaceuticals, where he was responsible for the drug development of Isis’ products across a range of therapeutic areas. He was instrumental in advancing more than a dozen antisense drugs from basic research to clinical development. Dr. Levin also held broad corporate responsibilities with investors and corporate partners. He joined Isis from Hoffmann-La Roche Inc. where he was Research Leader. Dr. Levin holds a PhD in Toxicology from the University of Rochester School of Medicine and Dentistry, New York and a BS in Biology from Muhlenberg College. He completed his post-doctoral work at the Chemical Industry Institute of Toxicology in Research Triangle, North Carolina. Dr. Levin is the author of more than 50 papers and book chapters.